Literature DB >> 10932682

Surgical intervention for the severely obese.

R J Albrecht1, W J Pories.   

Abstract

Severe obesity is a grave disease in the U.S. as well as other industrialized nations. This disease has many ramifications on both an individual and social levels. It affects 12.5 million people in the U.S., according to national survey data. The health risks of severe obesity include hypertension, hyperlipidaemia, cardiomyopathy, diabetes, hypoventilation disorders, increased risk of malignancy, cholelithiasis, degenerative arthritis, infertility, and psychosocial impairments. Medical weight reduction programmes have rarely achieved long-term success. Most authorities now agree that bariatric surgery is the treatment of choice for well-informed and motivated obese patients with acceptable operative risks, who strongly desire substantial weight loss or who have severe impairments because of their weight. Surgery is indicated for patients with a BMI greater than 40 kg/m2, or for those with serious medical co-morbidities and a BMI greater than 35 kg/m2. Three procedures, the adjustable silicone gastric banding (ASGB), vertical gastric banding (VBG), and gastric bypass (GB), have produced the best results to date. Each of these procedures is much more effective than dietary therapies. Each has advantages and disadvantages, with GB producing greater sustained weight loss in the long-term, with a slightly higher risk of metabolic complications. All can be done with surprisingly low operative mortality. The pronounced weight loss induced with these operations can relieve and bring co-morbid diseases, such as diabetes and hypertension, once thought to be only barely controllable, into full long-term remission.

Entities:  

Mesh:

Year:  1999        PMID: 10932682     DOI: 10.1053/beem.1999.0012

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Endocrinol Metab


  8 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Lifestyle modification in the management of obesity.

Authors:  Thomas A Wadden; Brian G McGuckin; Rebecca A Rothman; Stephanie L Sargent
Journal:  J Gastrointest Surg       Date:  2003 May-Jun       Impact factor: 3.452

3.  Diabetes and obesity: medical diseases, surgical cure?

Authors:  Vanita R Aroda; Michelle K Savu; Robert R Henry
Journal:  Curr Diab Rep       Date:  2004-10       Impact factor: 4.810

4.  The evaluation of gallstone formation in patients undergoing Roux-en-Y gastric bypass due to morbid obesity.

Authors:  Metin Karadeniz; Mehmet Görgün; Cemal Kara
Journal:  Ulus Cerrahi Derg       Date:  2014-06-01

5.  Short-, mid- and long-term results of Larrad biliopancreatic diversion.

Authors:  Alvaro Larrad-Jiménez; Carlos Sánchez-Cabezudo Díaz-Guerra; Pedro de Cuadros Borrajo; Irene Bretón Lesmes; Basilio Moreno Esteban
Journal:  Obes Surg       Date:  2007-02       Impact factor: 4.129

6.  Health risks of obesity.

Authors:  A M Ogunbode; A A Fatiregun; O O Ogunbode
Journal:  Ann Ib Postgrad Med       Date:  2009-12

7.  Predicting outcome of gastric bypass surgery utilizing personality scale elevations, psychosocial factors, and diagnostic group membership.

Authors:  Scott B Belanger; Frederick S Wechsler; Mahsaw Elicia Nademin; Thomas B Virden
Journal:  Obes Surg       Date:  2009-05-30       Impact factor: 4.129

8.  The utility of routine postoperative upper GI series following laparoscopic gastric bypass.

Authors:  Asok Doraiswamy; Jason J Rasmussen; Jonathan Pierce; William Fuller; Mohamed R Ali
Journal:  Surg Endosc       Date:  2007-05-19       Impact factor: 4.584

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.